This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hayes, G. M. Articles by Miller, L. J. Search for Related Content PubMed PubMed Citation Articles by Hayes, G. M. Articles by Miller, L. J.

Targeting the RNA Splicing Machinery as a Novel Treatment Strategy for Pancreatic Carcinoma

Mayo Clinic Cancer Center and the Department of Molecular Pharmacology and Experimental Therapeutics, Scottsdale, Arizona

Requests for reprints: Laurence J. Miller, Deputy Director, Mayo Clinic Cancer Center, 13400 East Shea Boulevard, Scottsdale, AZ 85259. Phone: 480-301-6650; Fax: 480-301-4596; E-mail: miller{at}mayo.edu.

Aberrant patterns of pre-mRNA splicing have been established for many human malignancies, yet the mechanisms responsible for these tumor-specific changes remain undefined and represent a promising area for therapeutic intervention. Using immunohistochemistry, we have localized the expression of a central splicing regulator, serine-arginine protein kinase 1 (SRPK1), to the ductular epithelial cells within human pancreas and have further shown its increased expression in tumors of the pancreas, breast, and colon. Small interfering RNA–mediated down-regulation of SRPK1 in pancreatic tumor cell lines resulted in a dose-dependent decrease in proliferative capacity and increase in apoptotic potential. Coordinately, the disruption of SRPK1 expression resulted in enhanced sensitivity of tumor cells to killing by gemcitabine and/or cisplatin. A dose-dependent reduction in the phosphorylation status of specific SR proteins was detected following the down-regulation of SRPK1 and is likely responsible for the observed alterations in expression of proteins associated with apoptosis and multidrug resistance. These data support SRPK1 as a new, potential target for the treatment of pancreatic ductular cancer that at present remains largely unresponsive to conventional therapies. Furthermore, these results support the development of innovative therapies that target not only specific splice variants arising during tumorigenesis but also the splice regulatory machinery that itself may be abnormal in malignant cells. (Cancer Res 2006; 66(7): 3819-27)

This article has been cited by other articles:

				L. Shkreta, U. Froehlich, E. R. Paquet, J. Toutant, S. A. Elela, and B. Chabot Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes Mol. Cancer Ther., June 1, 2008; 7(6): 1398 - 1409. [Abstract] [Full Text] [PDF]

				S. Gattenloehner, S. Chuvpilo, C. Langebrake, D. Reinhardt, H.-K. Muller-Hermelink, E. Serfling, A. Vincent, and A. Marx Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression Blood, September 15, 2007; 110(6): 2027 - 2033. [Abstract] [Full Text] [PDF]

				V. Filippov, M. Filippova, and P. J. Duerksen-Hughes The Early Response to DNA Damage Can Lead to Activation of Alternative Splicing Activity Resulting in CD44 Splice Pattern Changes Cancer Res., August 15, 2007; 67(16): 7621 - 7630. [Abstract] [Full Text] [PDF]

				G. M. Hayes, P. E. Carrigan, and L. J. Miller Serine-Arginine Protein Kinase 1 Overexpression Is Associated with Tumorigenic Imbalance in Mitogen-Activated Protein Kinase Pathways in Breast, Colonic, and Pancreatic Carcinomas Cancer Res., March 1, 2007; 67(5): 2072 - 2080. [Abstract] [Full Text] [PDF]